• Delcath Systems’ third-quarter 2026 net income rose to $6.95 million from a year earlier.
• Revenue climbed 71% year over year to $35.1 million.
• Cash and investments totaled $104.3 million at September 30, 2026, with no debt.
• The Phase 2 DELUMA trial dosed its first patient July 9, evaluating HEPZATO combination therapy in liver-dominant HER2-negative metastatic breast cancer.
• FY26 guidance targets revenue of $115 million to $117 million, with gross margins of 87% to 89%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Delcath Systems Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261109539034) on November 09, 2026, and is solely responsible for the information contained therein.